Rapport Therapeutics Inc Forecast, price target & analysts
Rapport Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Rapport Therapeutics Inc Classifications & Recommendation
Rapport Therapeutics Inc Price Target
| Target Price | $60.18 |
| Price | $32.19 |
| Potential |
86.95%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Rapport Therapeutics Inc 2027 .
The average Rapport Therapeutics Inc target price is $60.18.
This is
86.95%
register free of charge
$84.00
160.95%
register free of charge
$51.51
60.02%
register free of charge
|
|
| A rating was issued by 19 analysts: 18 Analysts recommend Rapport Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rapport Therapeutics Inc stock has an average upside potential 2027 of
86.95%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 20.40 |
15 Analysts have issued a sales forecast Rapport Therapeutics Inc 2026 . The average Rapport Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Rapport Therapeutics Inc EBITDA forecast 2026. The average Rapport Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Rapport Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Rapport Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.86 | -4.15 |
| 24.34% | 45.10% | |
| P/E | negative | |
| EV/Sales | 54.28 |
15 Analysts have issued a Rapport Therapeutics Inc forecast for earnings per share. The average Rapport Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Rapport Therapeutics Inc...
Current Rapport Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Sep 16 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 19 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jun 24 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | May 21 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 16 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 19 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jun 24 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
May 21 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
